DICE Therapeutics, Inc. (NASDAQ:DICE – Get Rating) was the target of a large decline in short interest during the month of August. As of August 31st, there was short interest totalling 5,220,000 shares, a decline of 7.8% from the August 15th total of 5,660,000 shares. Based on an average trading volume of 394,400 shares, the days-to-cover ratio is currently 13.2 days. Currently, 17.9% of the shares of the stock are short sold.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on DICE shares. Cantor Fitzgerald initiated coverage on DICE Therapeutics in a research report on Wednesday, September 14th. They issued an "overweight" rating and a $36.00 price target for the company. HC Wainwright initiated coverage on shares of DICE Therapeutics in a report on Monday, July 18th. They set a "buy" rating and a $40.00 price target on the stock. Finally, Stifel Nicolaus began coverage on DICE Therapeutics in a research report on Tuesday, September 6th. They issued a "buy" rating and a $37.00 target price for the company. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat, DICE Therapeutics presently has a consensus rating of "Buy" and a consensus price target of $43.33.

DICE Therapeutics Stock Up 0.9 %

Shares of DICE Therapeutics stock traded up $0.18 during trading on Wednesday, hitting $19.27. 4,206 shares of the stock traded hands, compared to its average volume of 512,305. DICE Therapeutics has a twelve month low of $12.64 and a twelve month high of $38.18. The company has a fifty day moving average price of $18.33 and a two-hundred day moving average price of $17.71.

Institutional Investors Weigh In On DICE Therapeutics

About DICE Therapeutics

(Get Rating)

DICE Therapeutics, Inc, a biopharmaceutical company, builds various oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas. Its platform DELSCAPE, is designed to discover selective oral small molecules to modulate protein-protein interactions (PPIs) as effectively as systemic biologics.

Further Reading

• Get a free copy of the StockNews.com research report on DICE Therapeutics (DICE)
• 3 Defensive Stocks With 60-Year Dividend Hike Streaks
• General Mills: Superior Returns With Less Volatility
• 3 Airline Stocks Stuck in a Holding Pattern
• Roku Stock is Down but Not Out
• If You're Hungry for Value, Take a Bite on Ruth's Hospitality Grp

Receive News & Ratings for DICE Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DICE Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.